These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16969071)

  • 21. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
    Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
    Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
    Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
    Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
    Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice.
    Peterson CM; Lu JM; Sun Y; Peterson CA; Shiah JG; Straight RC; Kopecek J
    Cancer Res; 1996 Sep; 56(17):3980-5. PubMed ID: 8752167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
    Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
    Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis increases sensitivity to detect cancer mutations in plasma.
    Marques JF; Junqueira-Neto S; Pinheiro J; Machado JC; Costa JL
    Eur J Cancer; 2020 Mar; 127():130-138. PubMed ID: 32007713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
    del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
    J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
    Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.
    De Souza R; Zahedi P; Badame RM; Allen C; Piquette-Miller M
    Mol Cancer Ther; 2011 Jul; 10(7):1289-99. PubMed ID: 21551263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
    Knecht R; Peters S; Solbach C; Baghi M; Gstöttner W; Hambek M
    Anticancer Res; 2003; 23(6C):4789-95. PubMed ID: 14981927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.